Advertisement

Clinical, Diagnostic, and Therapeutic Aspects of the Marfan Syndrome

  • Jason R. Cook
  • Francesco Ramirez
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 802)

Abstract

Marfan syndrome (MFS) is a relatively common and often lethal disease of connective tissue. Medical, surgical and basic research advances over the last two decades have had a major positive impact on the clinical management of MFS patients. Life expectancy has increased significantly, more discriminating diagnostic criteria have been developed, a number of new clinical entities have been recognized, and exciting opportunities for drug-based therapy have emerged. Despite such a remarkable progress, MFS diagnosis remains difficult and aortic disease progression is very heterogeneous and clinical outcome is unpredictable. Ongoing research efforts are therefore exploiting animal models of MFS to identify novel diagnostic and prognostic biomarkers, genetic, epigenetic and environmental modifiers and druggable biological targets.

Keywords

Marfan syndrome Mutations in gene for fibrillin-1 (FBN1Thoracic and abdominal aortic aneurysm Valvulopathy Ghent nosology β-blockers Calcium channel blockers Angiotensin receptor blockers (ARBs) Bone deformities 

Notes

Acknowledgments

Studies from the authors’ laboratory described in the review were supported by grants from the National Institutes of Health (AR-049698, AR-42044 and T32GM007280) and the National Marfan Foundation. We thank Ms. Karen Johnson for organizing the manuscript.

References

  1. 1.
    Pyeritz RE (2000) The Marfan syndrome. Annu Rev Med 51:481–510PubMedGoogle Scholar
  2. 2.
    Marfan A (1896) Un cas de déformation congénitale des quatre membres plus pronocée aux extrémites charactérisée par l’allongement des os avec uncertain degréd’amincissement. Bull Mem Soc Med Hop 13:220–226Google Scholar
  3. 3.
    McKusick VA (1955) Heritable disorders of connective tissue. III. The Marfan syndrome. J Chronic Dis 2:609–644PubMedGoogle Scholar
  4. 4.
    Dietz HC, Cutting CG, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, Stetten G, Meyers D, Francomano Clair A (1991) Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352:337–339PubMedGoogle Scholar
  5. 5.
    Lee B, Godfrey M, Vitale E, Hori H, Mattei M-G, Sarfarazi M, Tsipouras P, Ramirez F, Hollister D (1991) Linkage of Marfan syndrome and a phenotypically related disorder are linked to two different fibrillin genes. Nature 352:330–334PubMedGoogle Scholar
  6. 6.
    Sponseller PD, Erkula G, Skolasky RL, Venuti KD, Dietz HC (2010) Improving clinical recognition of Marfan syndrome. J Bone Joint Surg Am 92:1868–1875PubMedGoogle Scholar
  7. 7.
    Dean JC (2002) Management of Marfan syndrome. Heart 88:97–103PubMedGoogle Scholar
  8. 8.
    Gott VL, Greene PS, Alejo DE, Cameron DE, Naftel DC, Miller DC, Gillinov AM, Laschinger JC, Pyeritz RE (1999) Replacement of the aortic root in patients with Marfan’s syndrome. N Engl J Med 340:1307–1313PubMedGoogle Scholar
  9. 9.
    Ramirez F, Dietz H (2007) Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev 17:1–7Google Scholar
  10. 10.
    Geva T, Sanders SP, Diogenes MS, Rockenmacher S, Van Praagh R (1990) Two-dimensional and Doppler echocardiographic and pathologic characteristics of the infantile Marfan syndrome. Am J Cardiol 65:1230–1237PubMedGoogle Scholar
  11. 11.
    Buntinx IM, Willems PJ, Spitaels SE, Van Reempst PJ, De Paepe AM, Dumon JE (1991) Neonatal Marfan syndrome with congenital arachnodactyly, flexion contractures, and severe cardiac valve insufficiency. J Med Genet 28:267–273PubMedGoogle Scholar
  12. 12.
    Bresters D, Nikkels PG, Meijboom EJ, Hoorntje TM, Pals G, Beemer FA (1999) Clinical, pathological and molecular genetic findings in a case of neonatal Marfan syndrome. Acta Paediatr 88:98–101PubMedGoogle Scholar
  13. 13.
    Meijboom LJ, Timmermans J, van Tintelen JP, Nollen GJ, De Backer J, van den Berg MP, Boers GH, Mulder BJ (2005) Evaluation of left ventricular dimensions and function in Marfan’s syndrome without significant valvular regurgitation. Am J Cardiol 95:795–797PubMedGoogle Scholar
  14. 14.
    De Backer JF, Devos D, Segers P, Matthys D, Francois K, Gillebert TC, De Paepe AM, De Sutter J (2006) Primary impairment of left ventricular function in Marfan syndrome. Int J Cardiol 112:353–358PubMedGoogle Scholar
  15. 15.
    Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, Boxer M, Devereux RB, Tsipouras P (1995) Life expectancy in the Marfan syndrome. Am J Cardiol 75:157–160PubMedGoogle Scholar
  16. 16.
    van Karnebeek CD, Naeff MS, Mulder BJ, Hennekam RC, Offringa M (2001) Natural history of cardiovascular manifestations in Marfan syndrome. Arch Dis Child 84:129–137PubMedGoogle Scholar
  17. 17.
    Kiotsekoglou A, Sutherland GR, Moggridge JC, Nassiri DK, Camm AJ, Child AH (2009) The unravelling of primary myocardial impairment in Marfan syndrome by modern echocardiography. Heart 95:1561–1566PubMedGoogle Scholar
  18. 18.
    DeVore GR (2002) First-trimester fetal echocardiography: is the future now? Ultrasound Obstet Gynecol 20:6–8PubMedGoogle Scholar
  19. 19.
    Stadie R, Geipel A, Heep A, Herberg U, Welker B, Gembruch U, Berg C (2007) Prenatal diagnosis of Marfan syndrome. Ultrasound Obstet Gynecol 30:119–121PubMedGoogle Scholar
  20. 20.
    Lopes KR, Delezoide AL, Baumann C, Vuillard E, Luton D, Chitrit Y, Azancot A (2006) Prenatal Marfan syndrome: report of one case and review of the literature. Prenat Diagn 26:696–699PubMedGoogle Scholar
  21. 21.
    Geva T, Hegesh J, Frand M (1987) The clinical course and echocardiographic features of Marfan’s syndrome in childhood. Am J Dis Child 141:1179–1182PubMedGoogle Scholar
  22. 22.
    Nataatmadja M, West M, West J, Summers K, Walker P, Nagata M, Watanabe T (2003) Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in Marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 108(Suppl 1):II329–II334PubMedGoogle Scholar
  23. 23.
    Nagashima H, Sakomura Y, Aoka Y, Uto K, Kameyama K, Ogawa M, Aomi S, Koyanagi H, Ishizuka N, Naruse M, Kawana M, Kasanuki H (2001) Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan’s syndrome. Circulation 104:I282–I287PubMedGoogle Scholar
  24. 24.
    Niwa K, Perloff JK, Bhuta SM, Laks H, Drinkwater DC, Child JS, Miner PD (2001) Structural abnormalities of great arterial walls in congenital heart disease: light and electron microscopic analyses. Circulation 103:393–400PubMedGoogle Scholar
  25. 25.
    Sohn GH, Jang SY, Moon JR, Yang JH, Sung K, Ki CS, Oh JK, Choe YH, Kim DK (2011) The usefulness of multidetector computed tomographic angiography for the diagnosis of Marfan syndrome by Ghent criteria. Int J Cardiovasc Imaging 27:679–688PubMedGoogle Scholar
  26. 26.
    Nollen GJ, van Schijndel KE, Timmermans J, Groenink M, Barentsz JO, van der Wall EE, Stoker J, Mulder BJ (2002) Pulmonary artery root dilatation in Marfan syndrome: quantitative assessment of an unknown criterion. Heart 87:470–471PubMedGoogle Scholar
  27. 27.
    Streeten EA, Murphy EA, Pyeritz RE (1987) Pulmonary function in the Marfan syndrome. Chest 91:408–412PubMedGoogle Scholar
  28. 28.
    Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM (2010) The revised Ghent nosology for the Marfan syndrome. J Med Genet 47:476–485PubMedGoogle Scholar
  29. 29.
    Milewicz DM, Dietz HC, Miller DC (2005) Treatment of aortic disease in patients with Marfan syndrome. Circulation 111:e150–e157PubMedGoogle Scholar
  30. 30.
    Engelfriet PM, Boersma E, Tijssen JG, Bouma BJ, Mulder BJ (2006) Beyond the root: dilatation of the distal aorta in Marfan’s syndrome. Heart 92:1238–1243PubMedGoogle Scholar
  31. 31.
    Blanchard JF (1999) Epidemiology of abdominal aortic aneurysms. Epidemiol Rev 21:207–221PubMedGoogle Scholar
  32. 32.
    Antoniou GA, Georgiadis GS, Antoniou SA, Granderath FA, Giannoukas AD, Lazarides MK (2011) Abdominal aortic aneurysm and abdominal wall hernia as manifestations of a connective tissue disorder. J Vasc Surg 54:1175–1181PubMedGoogle Scholar
  33. 33.
    Choke E, Cockerill G, Wilson WR, Sayed S, Dawson J, Loftus I, Thompson MM (2005) A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg 30:227–244PubMedGoogle Scholar
  34. 34.
    Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110:625–632PubMedCentralPubMedGoogle Scholar
  35. 35.
    Aoki H, Yoshimura K, Matsuzaki M (2007) Turning back the clock: regression of abdominal aortic aneurysms via pharmacotherapy. J Mol Med (Berl) 85:1077–1088Google Scholar
  36. 36.
    Humphrey JD, Holzapfel GA (2012) Mechanics, mechanobiology, and modeling of human abdominal aorta and aneurysms. J Biomech 45:805–814PubMedCentralPubMedGoogle Scholar
  37. 37.
    Loeys B, Nuytinck L, Delvaux I, De Bie S, De Paepe A (2001) Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med 161:2447–2454PubMedGoogle Scholar
  38. 38.
    Waldmuller S, Muller M, Warnecke H, Rees W, Schols W, Walterbusch G, Ennker J, Scheffold T (2007) Genetic testing in patients with aortic aneurysms/dissections: a novel genotype/phenotype correlation? Eur J Cardiothorac Surg 31:970–975PubMedGoogle Scholar
  39. 39.
    Brown OR, DeMots H, Kloster FE, Roberts A, Menashe VD, Beals RK (1975) Aortic root dilatation and mitral valve prolapse in Marfan’s syndrome: an ECHOCARDIOgraphic study. Circulation 52:651–657PubMedGoogle Scholar
  40. 40.
    Pyeritz RE, Wappel MA (1983) Mitral valve dysfunction in the Marfan syndrome. Clinical and echocardiographic study of prevalence and natural history. Am J Med 74:797–807PubMedGoogle Scholar
  41. 41.
    Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, Lehman B, Benjamin EJ (1999) Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 341:1–7PubMedGoogle Scholar
  42. 42.
    Morse RP, Rockenmacher S, Pyeritz RE, Sanders SP, Bieber FR, Lin A, MacLeod P, Hall B, Graham JM Jr (1990) Diagnosis and management of infantile Marfan syndrome. Pediatrics 86:888–895PubMedGoogle Scholar
  43. 43.
    Sisk HE, Zahka KG, Pyeritz RE (1983) The Marfan syndrome in early childhood: analysis of 15 patients diagnosed at less than 4 years of age. Am J Cardiol 52:353–358PubMedGoogle Scholar
  44. 44.
    Ng DK, Chau KW, Black C, Thomas TM, Mak KL, Boxer M (1999) Neonatal Marfan syndrome: a case report. J Paediatr Child Health 35:321–323PubMedGoogle Scholar
  45. 45.
    Schroeyers P, Wellens F, De Geest R, Degrieck I, Van Praet F, Vermeulen Y, Vanermen H (2001) Minimally invasive video-assisted mitral valve surgery: our lessons after a 4-year experience. Ann Thorac Surg 72:S1050–S1054PubMedGoogle Scholar
  46. 46.
    Fujiseki Y, Okuno K, Tanaka M, Shimada M, Takahashi M, Kawanishi K (1985) Myocardial involvement in the Marfan syndrome. Jpn Heart J 26:1043–1050PubMedGoogle Scholar
  47. 47.
    Rybczynski M, Koschyk DH, Aydin MA, Robinson PN, Brinken T, Franzen O, Berger J, Hofmann T, Meinertz T, von Kodolitsch Y (2007) Tissue Doppler imaging identifies myocardial dysfunction in adults with Marfan syndrome. Clin Cardiol 30:19–24PubMedGoogle Scholar
  48. 48.
    Kiotsekoglou A, Bajpai A, Bijnens BH, Kapetanakis V, Athanassopoulos G, Moggridge JC, Mullen MJ, Nassiri DK, Camm J, Sutherland GR, Child AH (2008) Early impairment of left ventricular long-axis systolic function demonstrated by reduced atrioventricular plane displacement in patients with Marfan syndrome. Eur J Echocardiogr 9:605–613PubMedGoogle Scholar
  49. 49.
    Yetman AT, Bornemeier RA, McCrindle BW (2003) Long-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death? J Am Coll Cardiol 41:329–332PubMedGoogle Scholar
  50. 50.
    Alpendurada F, Wong J, Kiotsekoglou A, Banya W, Child A, Prasad SK, Pennell DJ, Mohiaddin RH (2010) Evidence for Marfan cardiomyopathy. Eur J Heart Fail 12:1085–1091PubMedGoogle Scholar
  51. 51.
    Kahveci G, Erkol A, Yilmaz F (2010) Dilated cardiomyopathy in a patient with Marfan syndrome accompanied by chronic type A aortic dissection and right atrial thrombus. Intern Med 49:2583–2586PubMedGoogle Scholar
  52. 52.
    Jeremy RW, Huang H, Hwa J, McCarron H, Hughes CF, Richards JG (1994) Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol 74:369–373PubMedGoogle Scholar
  53. 53.
    Grahame R, Pyeritz RE (1995) The Marfan syndrome: joint and skin manifestations are prevalent and correlated. Br J Rheumatol 34:126–131PubMedGoogle Scholar
  54. 54.
    Lundby R, Kirkhus E, Rand-Hendriksen S, Hald J, Pripp AH, Smith HJ (2011) CT of the hips in the investigation of protrusion acetabuli in Marfan syndrome. A case control study. Eur Radiol 21:1485–1491PubMedCentralPubMedGoogle Scholar
  55. 55.
    Le Parc JM, Molcard S, Tubach F (2001) Bone mineral density in Marfan syndrome. Rheumatology (Oxford) 40:358–359Google Scholar
  56. 56.
    Giampietro PF, Peterson M, Schneider R, Davis JG, Raggio C, Myers E, Burke SW, Boachie-Adjei O, Mueller CM (2003) Assessment of bone mineral density in adults and children with Marfan syndrome. Osteoporos Int 14:559–563PubMedGoogle Scholar
  57. 57.
    Fattori R, Nienaber CA, Descovich B, Ambrosetto P, Reggiani LB, Pepe G, Kaufmann U, Negrini E, von Kodolitsch Y, Gensini GF (1999) Importance of dural ectasia in phenotypic assessment of Marfan’s syndrome. Lancet 354:910–913PubMedGoogle Scholar
  58. 58.
    Ahn NU, Sponseller PD, Ahn UM, Nallamshetty L, Rose PS, Buchowski JM, Garrett ES, Kuszyk BS, Fishman EK, Zinreich SJ (2000) Dural ectasia in the Marfan syndrome: MR and CT findings and criteria. Genet Med 2:173–179PubMedGoogle Scholar
  59. 59.
    Sponseller PD, Bhimani M, Solacoff D, Dormans JP (2000) Results of brace treatment of scoliosis in Marfan syndrome. Spine 25:2350–2354PubMedGoogle Scholar
  60. 60.
    Sponseller PD, Hobbs W, Riley LH 3rd, Pyeritz RE (1995) The thoracolumbar spine in Marfan syndrome. J Bone Joint Surg Am 77:867–876PubMedGoogle Scholar
  61. 61.
    Vetter U, Mayerhofer R, Lang D, von Bernuth G, Ranke MB, Schmaltz AA (1990) The Marfan syndrome – analysis of growth and cardiovascular manifestation. Eur J Pediatr 149:452–456PubMedGoogle Scholar
  62. 62.
    Jones KB, Sponseller PD, Erkula G, Sakai L, Ramirez F, Dietz HC 3rd, Kost-Byerly S, Bridwell KH, Sandell L (2007) Symposium on the musculoskeletal aspects of Marfan syndrome: meeting report and state of the science. J Orthop Res 25:413–422PubMedGoogle Scholar
  63. 63.
    Zadeh N, Bernstein JA, Niemi AK, Dugan S, Kwan A, Liang D, Hyland JC, Hoyme HE, Hudgins L, Manning MA (2011) Ectopia lentis as the presenting and primary feature in Marfan syndrome. Am J Med Genet A 155A:2661–2668PubMedGoogle Scholar
  64. 64.
    Nahum Y, Spierer A (2008) Ocular features of Marfan syndrome: diagnosis and management. Isr Med Assoc J 10:179–181PubMedGoogle Scholar
  65. 65.
    Nemet AY, Assia EI, Apple DJ, Barequet IS (2006) Current concepts of ocular manifestations in Marfan syndrome. Surv Ophthalmol 51:561–575PubMedGoogle Scholar
  66. 66.
    De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE (1996) Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 62:417–426PubMedGoogle Scholar
  67. 67.
    Lee SY, Ang CL (2003) Results of retinal detachment surgery in Marfan syndrome in Asians. Retina 23:24–29PubMedGoogle Scholar
  68. 68.
    Sharma T, Gopal L, Shanmugam MP, Bhende PS, Agrawal R, Shetty NS, Gopalakrishna M, Rao MK, Balusamy S (2002) Retinal detachment in Marfan syndrome: clinical characteristics and surgical outcome. Retina 22:423–428PubMedGoogle Scholar
  69. 69.
    Tanoue LT (1992) Pulmonary involvement in collagen vascular disease: a review of the pulmonary manifestations of the Marfan syndrome, ankylosing spondylitis, Sjogren’s syndrome, and relapsing polychondritis. J Thorac Imaging 7:62–77PubMedGoogle Scholar
  70. 70.
    Hall JR, Pyeritz RE, Dudgeon DL, Haller JA Jr (1984) Pneumothorax in the Marfan syndrome: prevalence and therapy. Ann Thorac Surg 37:500–504PubMedGoogle Scholar
  71. 71.
    Wood JR, Bellamy D, Child AH, Citron KM (1984) Pulmonary disease in patients with Marfan syndrome. Thorax 39:780–784PubMedGoogle Scholar
  72. 72.
    Dwyer EM Jr, Troncale F (1965) Spontaneous pneumothorax and pulmonary disease in the Marfan syndrome. Report of two cases and review of the literature. Ann Intern Med 62:1285–1292PubMedGoogle Scholar
  73. 73.
    Karpman C, Aughenbaugh GL, Ryu JH (2011) Pneumothorax and bullae in Marfan syndrome. Respiration 82:219–224PubMedGoogle Scholar
  74. 74.
    Cipriano GF, Peres PA, Cipriano G Jr, Arena R, Carvalho AC (2010) Safety and cardiovascular behavior during pulmonary function in patients with Marfan syndrome. Clin Genet 78:57–65PubMedGoogle Scholar
  75. 75.
    Ledoux M, Beauchet A, Fermanian C, Boileau C, Jondeau G, Saiag P (2011) A case-control study of cutaneous signs in adult patients with Marfan disease: diagnostic value of striae. J Am Acad Dermatol 64:290–295PubMedGoogle Scholar
  76. 76.
    Judge DP, Dietz H (2005) Marfan’s syndrome. Lancet 366:1965–1976PubMedCentralPubMedGoogle Scholar
  77. 77.
    Faivre L, Collod-Beroud G, Ades L, Arbustini E, Child A, Callewaert B, Loeys B, Binquet C, Gautier E, Mayer K, Arslan-Kirchner M, Grasso M, Beroud C, Hamroun D, Bonithon-Kopp C, Plauchu H, Robinson P, De Backer J, Coucke P, Francke U, Bouchot O, Wolf J, Stheneur C, Hanna N, Detaint D, De Paepe A, Boileau C, Jondeau G (2011) The new Ghent criteria for Marfan syndrome: what do they change? Clin Genet 81:433–442PubMedGoogle Scholar
  78. 78.
    Sheikhzadeh S, Kade C, Keyser B, Stuhrmann M, Arslan-Kirchner M, Rybczynski M, Bernhardt A, Habermann C, Hillebrand M, Mir T, Robinson P, Berger J, Detter C, Blankenberg S, Schmidtke J, von Kodolitsch Y (2011) Analysis of phenotype and genotype information for the diagnosis of Marfan syndrome. Clin Genet 82(3):240–247PubMedGoogle Scholar
  79. 79.
    Maron BJ, Chaitman BR, Ackerman MJ, Bayes de Luna A, Corrado D, Crosson JE, Deal BJ, Driscoll DJ, 3rd Estes NA, Araujo CG, Liang DH, Mitten MJ, Myerburg RJ, Pelliccia A, Thompson PD, Towbin JA, Van Camp SP (2004) Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 109:2807–2816PubMedGoogle Scholar
  80. 80.
    Gersony DR, McClaughlin MA, Jin Z, Gersony WM (2007) The effect of β-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis. Int J Cardiol 114:303–308PubMedGoogle Scholar
  81. 81.
    Ladouceur M, Fermanian C, Lupoglazoff JM, Edouard T, Dulac Y, Acar P, Magnier S, Jondeau G (2007) Effect of β-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol 99:406–409PubMedGoogle Scholar
  82. 82.
    Salim MA, Alpert BS, Ward JC, Pyeritz RE (1994) Effect of β-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol 74:629–633PubMedGoogle Scholar
  83. 83.
    Selamet Tierney ES, Feingold B, Printz BF, Park SC, Graham D, Kleinman CS, Mahnke CB, Timchak DM, Neches WH, Gersony WM (2007) β-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr 150:77–82PubMedGoogle Scholar
  84. 84.
    Rossi-Foulkes R, Roman MJ, Rosen SE, Kramer-Fox R, Ehlers KH, O’Loughlin JE, Davis JG, Devereux RB (1999) Phenotypic features and impact of β blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 83:1364–1368PubMedGoogle Scholar
  85. 85.
    Williams A, Kenny D, Wilson D, Fagenello G, Nelson M, Dunstan F, Cockcroft J, Stuart G, Fraser AG (2012) Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome – a randomised, double-blind, crossover trial. Eur J Clin Invest 42(8):891–899PubMedGoogle Scholar
  86. 86.
    Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT (2007) Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116:1736–1754PubMedGoogle Scholar
  87. 87.
    Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd (2008) Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 358:2787–2795PubMedCentralPubMedGoogle Scholar
  88. 88.
    Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, Klein GL, Li JS, Minich LL, Paridon SM, Pearson GD, Printz BF, Pyeritz RE, Radojewski E, Roman MJ, Saul JP, Stylianou MP, Mahony L (2007) Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 154:624–631PubMedCentralPubMedGoogle Scholar
  89. 89.
    Gambarin FI, Favalli V, Serio A, Regazzi M, Pasotti M, Klersy C, Dore R, Mannarino S, Vigano M, Odero A, Amato S, Tavazzi L, Arbustini E (2009) Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. J Cardiovasc Med 10:354–362Google Scholar
  90. 90.
    Detaint D, Aegerter P, Tubach F, Hoffman I, Plauchu H, Dulac Y, Faivre LO, Delrue MA, Collignon P, Odent S, Tchitchinadze M, Bouffard C, Arnoult F, Gautier M, Boileau C, Jondeau G (2010) Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Arch Cardiovasc Dis 103:317–325PubMedGoogle Scholar
  91. 91.
    Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M (2010) Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials 11:3PubMedCentralPubMedGoogle Scholar
  92. 92.
    Yetman AT, Bornemeier RA, McCrindle BW (2005) Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 95:1125–1127PubMedGoogle Scholar
  93. 93.
    Pereira L, Konstantinos A, Tian J, Lee SY, Keene DR, Ono R, Reinhardt DP, Sakai LY, Jensen-Biery N, Bunton T, Dietz HC, Ramirez F (1997) Targeting of the gene coding fibrillin-1 recapitulates the vascular phenotype of Marfan syndrome in the mouse. Nat Genet 17:218–222PubMedGoogle Scholar
  94. 94.
    Bunton TE, Biery NJ, Gayraud B, Ramirez F, Dietz HC (2001) Phenotypic modulation of vascular smooth muscle cells contributes to elastolysis in a mouse model of Marfan syndrome. Circ Res 88:37–43PubMedGoogle Scholar
  95. 95.
    Xiong W, Knispel R, Dietz HC, Ramirez F, Baxter B (2008) T. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J Vasc Surg 47:166–172PubMedGoogle Scholar
  96. 96.
    Chung A, Yang HHC, Radomski MW, van Breemen C (2008) Long-Term doxycycline is more effective than Atenolol to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res 102:e73–e85PubMedGoogle Scholar
  97. 97.
    McLoughlin D, McGuinness J, Byrne J, Terzo E, Huuskonen V, McAllister H, Black A, Kearney S, Kay E, Hill AD, Dietz HC, Redmond JM (2011) Pravastatin reduces Marfan aortic dilation. Circulation 124:S168–S173PubMedGoogle Scholar
  98. 98.
    Xiong W, Meisinger T, Knispel R, Worth JM, Baxter BT (2012) MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome. Circ Res 110:e92–e101PubMedGoogle Scholar
  99. 99.
    Booms P, Ney A, Barthel F, Moroy G, Counsell D, Gille C, Guo G, Pregla R, Mundlos S, Alix AJ, Robinson PN (2006) A fibrillin-1-fragment containing the elastin-binding-protein GxxPG consensus sequence upregulates matrix metalloproteinase-1: biochemical and computational analysis. J Mol Cell Cardiol 40:234–246PubMedGoogle Scholar
  100. 100.
    Radonic T, de Witte P, Groenink M, de Waard V, Lutter R, van Eijk M, Jansen M, Timmermans J, Kempers M, Scholte AJ, Hilhorst-Hofstee Y, van den Berg MP, van Tintelen JP, Pals G, Baars MJ, Mulder BJ, Zwinderman AH (2012) Inflammation aggravates disease severity in Marfan syndrome patients. PLoS One 7:e32963PubMedCentralPubMedGoogle Scholar
  101. 101.
    Segura AM, Luna RE, Horiba K, Stetler-Stevenson WG, McAllister HA Jr, Willerson JT, Ferrans VJ (1998) Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan’s syndrome. Circulation 98:II331–II338PubMedGoogle Scholar
  102. 102.
    Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R (2009) Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 119:2209–2216PubMedGoogle Scholar
  103. 103.
    Abdul-Hussien H, Hanemaaijer R, Verheijen JH, van Bockel JH, Geelkerken RH, Lindeman JH (2009) Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg 49:741–749PubMedGoogle Scholar
  104. 104.
    Canadas V, Vilacosta I, Bruna I, Fuster V (2010) Marfan syndrome. Part 2: treatment and management of patients. Nat Rev Cardiol 7:266–276PubMedGoogle Scholar
  105. 105.
    Patel ND, Weiss ES, Alejo DE, Nwakanma LU, Williams JA, Dietz HC, Spevak PJ, Gott VL, Vricella LA, Cameron DE (2008) Aortic root operations for Marfan syndrome: a comparison of the Bentall and valve-sparing procedures. Ann Thorac Surg 85:2003–2011PubMedGoogle Scholar
  106. 106.
    Volguina IV, Miller DC, Lemaire SA, Palmero LC, Wang XL, Connolly HM, Sundt TM 3rd, Bavaria JE, Dietz HC, Milewicz DM, Coselli JS (2009) Valve-sparing and valve-replacing techniques for aortic root replacement in patients with Marfan syndrome: analysis of early outcome. J Thorac Cardiovasc Surg 137:641–649PubMedGoogle Scholar
  107. 107.
    Ramirez F, Sakai LY (2009) Biogenesis and function of fibrillin assemblies. Cell Tissue Res 339:71–82PubMedCentralPubMedGoogle Scholar
  108. 108.
    Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C, Gautier E, Callewaert B, Arbustini E, Mayer K, Arslan-Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N, Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Muti C, Plauchu H, Robinson PN, Ades LC, Biggin A, Benetts B, Brett M, Holman KJ, De Backer J, Coucke P, Francke U, De Paepe A, Jondeau G, Boileau C (2007) Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet 81:454–466PubMedCentralPubMedGoogle Scholar
  109. 109.
    Ramirez F, Rifkin DB (2009) Extracellular microfibrils: contextual platforms for TGFβ and BMP signaling. Curr Opin Cell Biol 21:616–622PubMedCentralPubMedGoogle Scholar
  110. 110.
    Tiecke F, Katzke S, Booms P, Robinson PN, Neumann L, Godfrey M, Mathews KR, Scheuner M, Hinkel GK, Brenner RE, Hovels-Gurich HH, Hagemeier C, Fuchs J, Skovby F, Rosenberg T (2001) Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40. Eur J Hum Genet 9:13–21PubMedGoogle Scholar
  111. 111.
    Loeys BL, Gerber EE, Riegert-Johnson D, Iqbal S, Whiteman P, McConnell V, Chillakuri CR, Macaya D, Coucke PJ, De Paepe A, Judge DP, Wigley F, Davis EC, Mardon HJ, Handford P, Keene DR, Sakai LY, Dietz HC (2010) Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med 2:23ra20PubMedCentralPubMedGoogle Scholar
  112. 112.
    Faivre L, Gorlin RJ, Wirtz MK, Godfrey M, Dagoneau N, Samples JR, Le Merrer M, Collod-Beroud G, Boileau C, Munnich A, Cormier-Daire V (2003) In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. J Med Genet 40:34–36PubMedGoogle Scholar
  113. 113.
    Le Goff C, Mahaut C, Wang LW, Allali S, Abhyankar A, Jensen S, Zylberberg L, Collod-Beroud G, Bonnet D, Alanay Y, Brady AF, Cordier MP, Devriendt K, Genevieve D, Kiper PO, Kitoh H, Krakow D, Lynch SA, Le Merrer M, Megarbane A, Mortier G, Odent S, Polak M, Rohrbach M, Sillence D, Stolte-Dijkstra I, Superti-Furga A, Rimoin DL, Topouchian V, Unger S, Zabel B, Bole-Feysot C, Nitschke P, Handford P, Casanova JL, Boileau C, Apte SS, Munnich A, Cormier-Daire V (2011) Mutations in the TGFβ binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias. Am J Hum Genet 89:7–14PubMedCentralPubMedGoogle Scholar
  114. 114.
    Sood S, Eldadah ZA, Krause WL, McIntosh I, Dietz HC (1996) Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome. Nat Genet 12:209–211PubMedGoogle Scholar
  115. 115.
    Ramirez F, Sakai LY, Dietz HC, Rifkin DB (2004) Fibrillin microfibrils: multipurpose extracellular networks in organismal physiology. Physiol Genomics 19:151–154PubMedGoogle Scholar
  116. 116.
    Hollister DW, Godfrey M, Sakai LY, Pyeritz RE (1990) Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N Engl J Med 323:152–159PubMedGoogle Scholar
  117. 117.
    Carta L, Smaldone S, Zilberberg L, Loch D, Dietz HC, Rifkin DB, Ramirez F (2009) p38 MAPK is an early determinant of promiscuous Smad2/3 signaling in the aortas of fibrillin-1 (Fbn1)-null mice. J Biol Chem 284:5630–5636PubMedGoogle Scholar
  118. 118.
    Habashi JP, Judge D, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Garielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:117–121PubMedCentralPubMedGoogle Scholar
  119. 119.
    Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC (2003) Dysregulation of TGFβ activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33:407–411PubMedGoogle Scholar
  120. 120.
    Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY (2003) Latent transforming growth factor -binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 278:2750–2757PubMedGoogle Scholar
  121. 121.
    Sengle G, Charbonneau NL, Ono RN, Sasaki T, Alvarez J, Keene DR, Bachinger HP, Sakai LY (2008) Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J Biol Chem 283:13874–13888PubMedGoogle Scholar
  122. 122.
    Pereira L, Lee SY, Gayraud B, Andrikopoulos K, Shapiro SD, Bunton T, Jensen Biery N, Dietz HC, Sakai LY, Ramirez F (1999) Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci U S A 96:3819–3823PubMedCentralPubMedGoogle Scholar
  123. 123.
    Nistala H, Lee-Arteaga S, Carta L, Cook JR, Smaldone S, Siciliano G, Rifkin AN, Dietz HC, Rifkin DB, Ramirez F (2010) Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum Mol Genet 19:4790–4798PubMedGoogle Scholar
  124. 124.
    Judge DP, Biery N, Keene DR, Geubtner J, Myers L, Huso DL, Sakai LY, Dietz HC (2004) Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 114:172–181PubMedCentralPubMedGoogle Scholar
  125. 125.
    Lim D-S, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian AJ (2001) Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103:789–791PubMedCentralPubMedGoogle Scholar
  126. 126.
    Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, Lariviere R (2005) Neutralization of transforming growth factor-β attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 23:1895–1903PubMedGoogle Scholar
  127. 127.
    Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N (2004) Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-β1. Am J Physiol Renal Physiol 286:F278–F287PubMedGoogle Scholar
  128. 128.
    Carta L, Pereira L, Arteaga-Solis E, Lee-Arteaga SY, Lenart B, Starcher B, Merkel CA, Sukoyan M, Kerkis A, Hazeki N, Keene DR, Sakai LY, Ramirez F (2006) Fibrillins 1 and 2 perform partially overlapping functions during aortic development. J Biol Chem 281:8016–8023PubMedCentralPubMedGoogle Scholar
  129. 129.
    Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC (2011) Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332:361–365PubMedCentralPubMedGoogle Scholar
  130. 130.
    Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME, Kim D, Schoenhoff F, Cohn RD, Loeys BL, Thomas CJ, Patnaik S, Marugan JJ, Judge DP, Dietz HC (2011) Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332:358–361PubMedCentralPubMedGoogle Scholar
  131. 131.
    Cook JR, Nistala H, Ramirez F (2010) Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients. Mt Sinai J Med 77:366–373PubMedCentralPubMedGoogle Scholar
  132. 132.
    Nistala H, Lee-Arteaga S, Smaldone S, Siciliano G, Carta L, Ono RN, Sengle G, Arteaga-Solis E, Levasseur R, Ducy P, Sakai LY, Karsenty G, Ramirez F (2010) Fibrillin-1 and -2 differentially modulate endogenous TGFβ and BMP bioavailability during bone formation. J Cell Biol 190:1107–1121PubMedGoogle Scholar
  133. 133.
    Alliston T, Piek E, Derynck R (2008) TGFβ family signaling in skeletal development, maintenance and disease. In: Derynck R, Miyazono K (eds) The TGFβ family. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 667–723Google Scholar
  134. 134.
    Janssens K, ten Dijke P, Janssens S, Van Hul W (2005) Transforming growth factor-β1 to the bone. Endocr Rev 26:743–774PubMedGoogle Scholar
  135. 135.
    Cook JR, Smaldone S, Cozzolino C, Del Solar M, Lee-Arteaga S, Nistala H, Ramirez F (2012) Generation of Fbn1 conditional null mice implicates the extracellular microfibrils in osteoprogenitor recruitment. Genesis 50(8):635–641PubMedCentralPubMedGoogle Scholar
  136. 136.
    Gigante A, Chillemi C, Greco F (1999) Changes of elastic fibers in musculoskeletal tissues of Marfan syndrome: a possible mechanism of joint laxity and skeletal overgrowth. J Pediatr Orthop 19:283–288PubMedGoogle Scholar
  137. 137.
    Kronenberg HM (2007) The role of the perichondrium in fetal bone development. Ann N Y Acad Sci 1116:59–64PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Department of Pharmacology and Systems TherapeuticsIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations